New treatments in ulcer healing and wound infection.
This review examines several of the recently introduced wound care products that have been put forward as treatment modalities for the diabetic foot ulcer. Discussed are the results of clinical trials with the platelet-derived growth factor, becaplermin, the tissue-engineered products Dermagraft and Apligraf, and Hyaff which is an ester of hyaluronic acid. In patients with an infected foot ulcer, encouraging results were obtained with the granulocyte-colony stimulating factor, Filgrastim.
Edmonds
M
M
King's College Hospital, London, UK.
Bates
M
M
Doxford
M
M
Gough
A
A
Foster
A
A
D000077214:Becaplermin; D003094:Collagen / Q000627:therapeutic use*; D017719:Diabetic Foot / Q000628:therapy*; D016523:Foot Ulcer / Q000628:therapy; D016179:Granulocyte Colony-Stimulating Factor / Q000502:physiology / Q000627:therapeutic use; D006801:Humans; D010982:Platelet-Derived Growth Factor / Q000627:therapeutic use; D020574:Proto-Oncogene Proteins c-sis; D017768:Skin, Artificial; D014945:Wound Healing
D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D016179:Granulocyte Colony-Stimulating Factor; D000077214:Becaplermin; D003094:Collagen